A former Marine whose military experiences left him with post-traumatic stress disorder, commonly abbreviated as PTSD, is undergoing a clinical trial that has thus far shown a lot of promise for other veterans who suffer from this condition.
Mark Bratton served in Iraq and Afghanistan from 2007 to 2009; he was later diagnosed with PTSD and was forced to endure depression, anxiety and neurotic behavior. More than 2.5 million veterans suffer from PTSD, and most of them are prescribed medications such as Zoloft and Paxil, which were modeled after the successful Prozac came on the market to treat symptoms patients who suffer from depression.
In Bratton’s case, a service dog and a sublingual trial medication that contains a muscle relaxant have been very effective in terms of containing his PTSD symptoms. The medication is currently in its third stage of clinical trials in Texas, and has not yet been named.
According to television news station KGW, an NBC affiliate in Portland, the medication does not go directly into the bloodstream and does not present the typical side effects of drowsiness. Although the current trials feature veterans as test subjects, the medication will also be helpful to civilians whose PTSD symptoms are triggered by emotionally traumatic experiences.
The Food and Drug Administration has placed the trial medication into a fast-track phase for the purpose of making it available as soon as possible. This acceleration of trials is only granted to medications that show lots of promise and a high level of confidence in their effectiveness.